Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Affiliations

• ¹ Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
• ² Royal Hobart Hospital, Tasmania, Australia.
• ³ University of North Carolina, Chapel Hill, NC.
• ⁴ University of Arizona Cancer Center, Tuscon, AZ.
• ⁵ University of California, San Diego, San Diego, CA.
• ⁶ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
• ⁷ Weill Cornell Medicine, New York, NY.
• ⁸ University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
• ⁹ Hackensack University Medical Center, Hackensack, NJ.
• ¹⁰ Northwell Health Cancer Institute, Lake Success, NY.
• ¹¹ University of Pennsylvania, Philadelphia, PA.
• ¹² University of Colorado Cancer Center, Denver, CO.
• ¹³ Novant Health, Charlotte, NC.
• ¹⁴ Dartmouth-Hitchcock Medical Center, Lebanon, NH.
• ¹⁵ Colchester General Hospital, East Suffolk, and North Essex NHS Foundation Trust, Essex, United Kingdom.
• ¹⁶ The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, United Kingdom.
• ¹⁷ Roche Products Ltd, Welwyn Garden City, United Kingdom.
• ¹⁸ Genentech, Inc., South San Francisco, CA.
• ¹⁹ AbbVie, Inc., North Chicago, IL.
• ²⁰ Riverside Regional Medical Center, Newport News, VA.
• ²¹ Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
• ²² Amsterdam University Medical Centers, Amsterdam, The Netherlands; and.
• ²³ Royal Melbourne Hospital, Peter McCallum Cancer Centre, and University of Melbourne, Melbourne, Australia.